Targeting CCR4 "Moglizumab" submits a listing application in China

Source: Guanlan Pharmaceutical

On July 2, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Kylin Kylin (China) Pharmaceutical Co.

Screenshot source: CDE official website

Mogamulizumab (KW-0761) is a humanized CC chemikon receptor 4 (CCR4) monoclonal antibody developed by Kyowa Hakko Kirin

In an open-label, multi-center, randomized phase 3 trial called MAVORIC, a total of 372 patients with mycosis fungoides and Sezari syndrome received mogamulizumab or control drugs

Based on the results of this research, the FDA approved mogamulizumab in August 2018 to treat adult patients with relapsed or refractory mycosis fungoides or Sezari syndrome who have received at least one systemic therapy

Cutaneous T-cell lymphoma is a rare type of non-Hodgkin's lymphoma.

Therefore, cutaneous T-cell lymphoma may involve the skin, blood, lymph nodes, and internal organs, with the risk of disfigurement and debilitating

Reference materials:

[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.

[3] Kyowa Hakko Kirin: Announces Positive Results of the Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma.

[4] China's original innovative drug Chidamide has landed in overseas markets-Chippen Biosciences overseas partner Huya Biotechnology recently announced that Chidamide has been approved for listing in Japan.